Source: Covid Medical Network Presented by: Dr Eamonn Mathieson and Ben Bornstein

EARLY COVID TREATMENTS: Guest Speaker with the Covid Medial Network – Dr Ananda Prasad

New Covid Medical Network Webinar – “the absurd omission of Zinc” – Our interview with the Guru of Zinc

A few days ago the Covid Medical Network were honoured with the opportunity to interview Professor Ananda Prasad – who I think of as The Guru of Zinc.

At 92, Dr Prasad is still pursuing research and has had a clinical trial for the early-stage treatment using Zinc and HCQ kept in a holding pattern since April by the FDA who refuse to allow him to continue using HCQ; oddly so many other clinical trials have been “allowed” to proceed with what could only be considered the absurd omission of Zinc (after reviewing this video).

With a career spanning over six decades and drawing upon his knowledge of papers he was read that date as far back as 1869, Dr Prasad uses common sense and keen ON THE FRONT LINE observations to unlock the antiviral opportunities that present themselves with the right delivery of Zinc.

At 92, some 58 years after he first wrote his paper suggesting the role Zinc might play in CELL MEDIATED IMMUNITY, Dr Prasad and his wife caught Covid19 and successfully applied the principles of his theory with the Zinc Ionophore he sought out to ensure its success; HCQ.

Knowing that the theory and observations date so far back should provide significant confidence, well ahead of RCTs blocked or allowed, that Zinc and an effective delivery mechanism is a part of an early treatment protocol that ought to be available to all Doctors and their patients at their request.

Related: How hydroxychloroquine works at the cellular level

TGA banned a functioning treatment & Australian doctors want answers – Urgent request for revocation of HCQ ban

‘Only a one in 17 billion chance hydroxychloroquine doesn’t work’: medical professor

HCQ Protocols from America’s Frontline Doctors

Share on facebook
Share on twitter
Share on whatsapp
On Trend

Latest Stories

American Hero: Ralph C. Lorigo Fights for Client Rights Including Access to Ivermectin for COVID-19 Patients At Risk

Lorigo shared with TrialSite that once doctors learn of all of the studies around the world, and start doing their own homework, they become more open-minded, factoring in the risk-reward analysis. Especially if elderly high risk patients present advanced COVID-19, Lorigo has personally seen the drug potentially contribute to saving the lives of clients. Interestingly, the attorney reports that it would appear that hospital administrations are the most recalcitrant to the idea, even if the patients and the ICU doctor are in support.

Read More »

The Chloroquine Wars Part XIV – How to Rig Research: Surgisphere Part I

It was in these very moments in late May when public health officials lost all credibility—a credibility that cannot be restored without major changes taking place. Despite most evidence pointing to a likelihood of HCQ efficacy, they made their call on the back of data supposedly tucked away in a database that nobody had verified, declared it definitive, then swiftly pushed for policy changes around the world.

Read More »